Despite revolutionizing cancer management, immunotherapies dysregulate the immune
system, leading to immune-mediated adverse events. These common and potentially …

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for
numerous malignancies. However, due to their association with autoimmunity, ICIs have …

Importance Immune checkpoint inhibitor (ICI) monotherapy with pembrolizumab and ICI plus
chemotherapy have been approved as first-line treatments for non–small cell lung cancer …

Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …

Importance Systemic steroids are commonly used to manage immune-related adverse
events (irAEs), but it remains unclear whether they may undermine immune checkpoint …

Simple Summary There is a need to improve the conventional treatment options for lung
cancer. Immunotherapy is based on the premise that therapeutic drugs destroy tumor cells …

Introduction Cancer is a major global health concern, and immune checkpoint inhibitors
(ICIs) offer a promising treatment option for cancer patients. However, the efficacy of ICIs can …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell
death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly …

Background Previous studies indicate that exogenous use of glucocorticoid (GC) affects
immune checkpoint inhibitor (ICI) efficacy. However, there is a paucity of clinical data …

Simple Summary Since the approval of immune checkpoint inhibitors for solid tumors,
concerns have been raised about the role of the microbiota on immunotherapy success and …